Imatinib for the treatment of hypereosinophilic syndromes

Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing

(2017) Jee-Soo Lee et al.   PLoS One

Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome

(2016) P. Khoury et al.   ALLERGY

Myeloid neoplasms with eosinophilia

(2016) Andreas Reiter et al.   BLOOD

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

(2016) D. A. Arber et al.   BLOOD

Imatinib mesylate for unmutated hypereosinophilic syndromes: Does it work?

(2016) Grzegorz Helbig   European Journal of Internal Medicine

Characterization of leukemias with ETV6-ABL1 fusion

(2016) M. Zaliova et al.   HAEMATOLOGICA

Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China

(2016) Shi-Qiang Qu et al.   Oncotarget

Characterization of leukemias with ETV6-ABL1 fusion

(2016) M. Zaliova et al.   HAEMATOLOGICA

Imatinib discontinuation for hypereosinophilic syndrome harboring theFIP1L1-PDGFRAtranscript

(2015) Grzegorz Helbig et al.   LEUKEMIA & LYMPHOMA

The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia

(2014) A. H. Schmitt-Graeff et al.   BLOOD

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA

(2014) Irina Sadovnik et al.   EXPERIMENTAL HEMATOLOGY

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

(2014) B Hanfstein et al.   LEUKEMIA

IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW

(2014) Tomasz Sacha   Mediterranean Journal of Hematology and Infectious Diseases

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

FIP1L1-PDGFRα-Positive Hypereosinophilic Syndrome in Childhood

(2013) Piero Farruggia et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

(2013) G Metzgeroth et al.   LEUKEMIA

Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature

(2013) Jenna C. Podjasek et al.   LEUKEMIA RESEARCH

The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia

(2013) Fanny Legrand et al.   MEDICINE

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes

(2012) Peter Valent et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome

(2012) A Pardanani et al.   LEUKEMIA

Myeloid neoplasms with eosinophilia andFIP1L1–PDGFRAfusion gene: another point of view

(2012) Grzegorz Helbig et al.   LEUKEMIA & LYMPHOMA

Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease

(2011) C. Elling et al.   BLOOD

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia

(2011) Grzegorz Helbig et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation

(2011) G Metzgeroth et al.   LEUKEMIA

Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence

(2010) Martin M. Crane et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes

(2009) Tamara Intermesoli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy

(2009) Princess U. Ogbogu et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome

(2009) Joseph H. Butterfield   LEUKEMIA RESEARCH

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome - a phase-II study

(2008) Georgia Metzgeroth et al.   BRITISH JOURNAL OF HAEMATOLOGY

A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients

(2008) Grzegorz Helbig et al.   BRITISH JOURNAL OF HAEMATOLOGY

Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRα mutation status

(2008) Nitin Jain et al.   LEUKEMIA RESEARCH